Melbourne (Australia) | 27 May 2024

Telix today announces two abstract presentations featuring the Company’s therapeutic radiopharmaceutical programs at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 31 – June 4, 2024.

Oliver Sartor MD, Professor at Mayo Clinic (Rochester, MN) will present Telix’s ProstACT GLOBAL study of TLX591 (lutetium Lu 177 rosopatamab tetraxetan), the first Phase III trial to evaluate the radio antibody-drug conjugate (rADC) approach in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC).

Eric Jonasch, MD, Professor at MD Anderson Cancer Center (Houston, TX) will present the Phase II STARLITE-1 investigator-initiated trial of Telix’s carbonic anhydrase IX (CAIX)-targeting investigational therapy, TLX250 (177Lu-DOTA-girentuximab), in combination with immunotherapy in clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.

Come and meet the team at booth #21148 to discuss Telix’s extensive theranostic pipeline, our associated medical devices and artificial intelligence (AI), and opportunities for collaboration.

ASCO presentation details are as follows (all times CDT):

Title: ProstACT GLOBAL: A Phase III study of best standard of care with and without TLX591 for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug

Presenter: Oliver Sartor, MD, Mayo Clinic

Date and Time: Sunday, June 2 | 9:00 am – 12:00pm

Session: Genitourinary Cancer – Prostate, Testicular, and Penile

Abstract ID: TPS5115 (Poster Bd 517a)

Location: Hall A & On Demand

Title: STARLITE-1: A Phase Ib/II study of combination TLX250 plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC

Presenter: Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center

Date and Time: Sunday, June 2 | 9:00 am – 12:00pm

Session: Genitourinary Cancer – Kidney and Bladder

Abstract ID: TPS4610 (Poster Bd 303b)

Location: Hall A & On Demand

For more information and to register, visit here.

TLX591 and TLX250 have not received marketing authorisation in any jurisdiction.